WRIB 2020 -- IgG4-based therapeutics are a small but growing class of monoclonal antibodies employed for various patient treatments. The unique structure of the IgG4 molecule minimizes antibody and complement-dependent cytotoxicity, making it ideal for specific therapeutic purposes where 'silencing' of a target protein is required.

WRIB 2020 -- Antibody-drug conjugates (ADCs) are a novel class of therapeutic agents, in which one or more small cytotoxic molecules (payload) are linked covalently to a monoclonal antibody (mAb). The exposure of unconjugated payload and/or its metabolites in circulation is important for the evaluation of the safety and efficacy of ADCs.

AACR 2020 -- Informed selection of syngeneic models for use in preclinical drug development is critical for success. CT26 colorectal and 4T1-Luc breast tumors were treated with anti-mCTLA-4 to address how the tumor microenvironment influences therapeutic outcome.

AACR 2020 -- The degree of methylation in the promoter region of the O-6-methylguanine-DNA methyltransferase (MGMT) gene is widely accepted as a prognostic biomarker of patient outcomes in Glioblastoma multiforme (GBM).

AACR 2020 -- The continual pressure to develop molecules that target the immune system requires that there are new, reliable and well-characterized preclinical models available.

AACR 2020 -- The complex and dynamic nature of the tumor-immune microenvironment (TME) presents challenges for identification of robust and predictive biomarkers in immuno-oncology (IO).

AACR 2020 -- Breast cancer is generally regarded as an immunologically "cold" cancer, often with minimal tumor CD8+ T cell infiltrate and low immunogenicity.